Eptinezumab Infusion Associated with Meaningful Reductions in Daily Migraine Activity on Day 1 and Over Weeks 1 Through 4 in Patients with Frequent Episodic Migraine: Results of the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial

被引：0

作者：

Cady, Roger ^{[1
]}

Smith, Timothy ^{[2
]}

Biondi, David ^{[1
]}

Berman, Gary ^{[3
]}

Freeman, Marshall ^{[4
]}

Hirman, Joe ^{[5
]}

Kassel, Eric ^{[1
]}

机构：

[1] Alder BioPharmaceut Inc, Bothell, WA USA

[2] StudyMetrix Res LLC, St Louis, MO USA

[3] Clin Res Inst, Minneapolis, MN USA

[4] Headache Wellness Ctr, Greensboro, NC USA

[5] Pacific Northwest Stats, Bothell, WA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

PO-01-199

引用

页码：341 / 342

页数：2